Table 1.
Clinical trial inclusion and exclusion criteria.
Fig 1.
Flow diagram of the clinical trial.
Table 2.
Demographic and clinical data and baseline ACT variables.
Fig 2.
Change in children’s and parents’ enjoyment.
(A) Children's and (B) parents' enjoyment. Enjoyment was assessed on 7-point Likert-type scales, where—3 was the least enjoyment, + 3 was the most enjoyment, and 0 was neutral. Values were measured at baseline and in the final interviews. The data are presented as the mean (± SD). Wilcoxon test was performed to compare the differences between the baseline and final measures in each group. Changes in children’s enjoyment: *p = 0.004 (Treated Group); &p = 0.035 (Placebo Group); p = 0.89 (Control Group). Changes in parents’ enjoyment: *p = 0.009 (Treated Group); p = 0.096 (Placebo Group); p = 0.492 (Control Group).
Fig 3.
To analyze the perception of time, the apparent time value reported on the questionnaire was subtracted from the actual time value given (actual time—apparent time = perception of time). Positive value: perception of ACT shorter. Negative value: perception of ACT longer. Values above 0: participants felt they spent less time taking the ACT routine than the actual time they spent to taking it. Values below 0: participants felt they spent more time taking the ACT routine than the actual time they spent taking it. Differences were calculated at baseline and the final interviews. The data are presented as the mean (± SD). Wilcoxon test was performed to compare the differences between the baseline and final measures in each group. Changes: *p = 0.003 (Treated Group); p = 0.076 (Placebo Group); p = 0.857 (Control Group).
Table 3.
Healthcare resources in children with cystic fibrosis according to the different groups.